openpr.com
Cure8 news brief
Why This Matters
Market shifts — including more biosimilars, expanding biologic and small-molecule options, and wider online pharmacy access — can affect how quickly and affordably new Crohn’s treatments reach patients. Patients on biologics or considering newer drugs may see more choices and possibly lower costs over time.
Who Should Pay Attention
Adult patients with Crohn’s disease, caregivers, clinicians treating IBD, and researchers or industry stakeholders tracking drug availability and market trends.
Study Snapshot
Story typePress release
Evidence typeMarket or Business News
Source depthFull source text
What To Know
This is a market research / industry report summary covering projected market growth, key companies, and trends in Crohn’s disease treatment, including mentions of biologics, biosimilars (e.g., biosimilar ustekinumab/Pyzchiva), small molecules, and common drug classes used in Crohn’s care.
The piece highlights market drivers such as increased biologic and small-molecule pipelines, adoption of biosimilars to broaden access, online pharmacy growth, and commercial activity (e.g., Merck’s acquisition of Prometheus). It is a commercial market analysis rather than clinical guidance.
If you’re looking for clinical advice about treatments or the implications of specific drugs for individual care, discuss with your gastroenterology clinician; this article is about market trends and product availability rather than new clinical trial results.
Keep In Mind
This is a commercial market report summary and not primary clinical research. It references product launches and corporate activity (e.g., Sandoz Pyzchiva launch, Merck acquisition) to illustrate market trends; it does not present new clinical trial data or treatment recommendations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationopenpr.com
AuthorsThe Business Research Company
Indexed viaGoogle News
Source typeWeb article
PublishedJul 31, 2026, 2:48 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FDA Approves Interchangeability Designation for Teva and Alvotech’s Stelara Biosimilar Selarsdi for Multiple Indications
An interchangeable biosimilar to ustekinumab could expand access and lower costs for people with Crohn’s disease and ulcerative colitis who use Stelara. Pharmacists may be able to substitute the biosimilar for the...
Adalimumab May Help Maintain Remission in Crohn's Disease - Medscape
A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.